Adgero Biopharmaceuticals

Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline through the development of its proprietary late-stage photodynamic therapy (PDT) platform, which has broad applicability for the treatment of serious oncology indications. Its lead candidate, REM-001 Therapy, has demonstrated safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer (CMBC) who have failed radiation therapy.